SECURITIES AND EXCHANGE COMMISSION

FORM 6-K

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Filing Date: **2013-01-09** | Period of Report: **2013-01-09**
SEC Accession No. 0001191638-13-000043

(HTML Version on secdatabase.com)

FILER

GLAXOSMITHKLINE PLC

CIK:**1131399**| IRS No.: **000000000**
Type: **6-K** | Act: **34** | File No.: **001-15170** | Film No.: **13520086**
SIC: **2834** Pharmaceutical preparations

Mailing Address
980 GREAT WEST ROAD
BRENTFORD MIDDLESEX X0
TW8 9GS

Business Address
980 GREAT WEST ROAD
BRENTFORD MIDDLESEX X0
TW8 9GS
011442080475000

Copyright © 2013 www.secdatabase.com. All Rights Reserved.
Please Consider the Environment Before Printing This Document

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending January 2013

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

Copyright © 2013 www.secdatabase.com. All Rights Reserved.
Please Consider the Environment Before Printing This Document

The Administrators of the GlaxoSmithKline US Deferred Performance Share Plan notified the Company and the under-mentioned person on 8 January 2013 of the following increase in his interests in American Depositary Shares (ADSs) at a price of $43.98 per ADS following the re-investment of the dividend paid to shareholders on 3 January 2013.

	ADSs
Mr D E Troy	323.047

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Company Secretary

9 January 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: January 9, 2013

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc

Copyright © 2013 www.secdatabase.com. All Rights Reserved.
Please Consider the Environment Before Printing This Document